Severe	severe	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
patient	patient	O	O	O	O
on	on	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
presenting	presenting	O	O	O	O
with	with	O	O	O	O
myxedemic	myxedemic	O	O	O	O
coma	coma	O	DISEASE	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
myxedema	myxedema	O	O	O	O
coma	coma	O	DISEASE	OTHERS	I
secondary	secondary	O	O	O	O
to	to	O	O	O	O
amiodarone-induced	amiodarone-induced	O	O	O	O
hypothyroidism	hypothyroidism	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
our	our	O	O	O	O
knowledge	knowledge	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
reviewing	reviewing	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
one	one	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
myxedema	myxedema	O	O	O	O
coma	coma	O	DISEASE	OTHERS	I
during	during	O	O	O	O
long	long	O	O	O	O
term	term	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Myxedema	myxedema	O	O	O	O
coma	coma	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
life	life	O	O	O	O
threatening	threatening	O	O	O	O
condition	condition	O	O	O	O
that	that	O	O	O	O
carries	carries	O	O	O	O
a	a	O	O	O	O
mortality	mortality	O	O	O	O
reaching	reaching	O	O	O	O
as	as	O	O	O	O
high	high	O	O	O	O
as	as	O	O	O	O
20	20	O	O	O	O
%	%	O	O	O	O
with	with	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
condition	condition	O	O	O	O
is	is	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
thyroxine	thyroxine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
T4	t4	O	O	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
intravenous	intravenous	O	O	O	O
tri-iodo-thyronine	tri-iodo-thyronine	O	O	O	O
(	(	O	O	O	O
T3	t3	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
with	with	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
on	on	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
suffer	suffer	O	O	O	O
serious	serious	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
from	from	O	O	O	O
hypothyroidism	hypothyroidism	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
thus	thus	O	O	O	O
may	may	O	O	O	O
deserve	deserve	O	O	O	O
closer	closer	O	O	O	O
follow	follow	O	O	O	O
up	up	O	O	O	O
for	for	O	O	O	O
thyroid	thyroid	O	O	O	O
stimulating	stimulating	O	O	O	O
hormone	hormone	O	O	O	O
(	(	O	O	O	O
TSH	tsh	O	O	O	O
)	)	O	O	O	O
levels	levels	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
carries	carries	O	O	O	O
an	an	O	O	O	O
important	important	O	O	O	O
clinical	clinical	O	O	O	O
application	application	O	O	O	O
given	given	O	O	O	O
the	the	O	O	O	O
frequent	frequent	O	O	O	O
usage	usage	O	O	O	O
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
among	among	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
myriad	myriad	O	O	O	O
clinical	clinical	O	O	O	O
presentation	presentation	O	O	O	O
of	of	O	O	O	O
myxedema	myxedema	O	O	O	O
coma	coma	O	DISEASE	OTHERS	I
and	and	O	O	O	O
its	its	O	O	O	O
serious	serious	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
stresses	stresses	O	O	O	O
the	the	O	O	O	O
need	need	O	O	O	O
to	to	O	O	O	O
suspect	suspect	O	O	O	O
this	this	O	O	O	O
clinical	clinical	O	O	O	O
syndrome	syndrome	O	O	O	O
among	among	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
presenting	presenting	O	O	O	O
with	with	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
weakness	weakness	O	DISEASE	OTHERS	I
or	or	O	O	O	O
other	other	O	O	O	O
unexplained	unexplained	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

